Translational nanomedicine-Through the therapeutic window

Nanomedicine

Volumn 10, Issue 21, 2015, Pages 3249-3260

  Pierce, Robin L ^a  

^a HARVARD LAW SCHOOL   (United States)

Author keywords

Nanoethics; nanomedicine; patient centered research; therapeutic window; translational research

Indexed keywords

HUMAN; NANOMEDICINE; PRIORITY JOURNAL; REVIEW; TEMPORAL ANALYSIS; THERAPY EFFECT; TRANSLATIONAL RESEARCH;

HUMANS; NANOMEDICINE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84944334683     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.168     Document Type: Review

References (41)

1. Armstrong D. The rise of surveillance medicine. Sociol. Health Illness 17(3), 393-404 (1995).
2. Merriam-Webster. www.merriam-webster.com/medical/therapeutic
3. Pierce RL. Bridging current issues in science and society. Biotechnol J. 8(8), 875-877 (2013).
4. Steinbrook R. Organ donation after cardiac death. N. Engl. J. Med. 357(3) 209-213 (2007).
5. Lupton D. Health promotion in the digital era: a critical commentary. Health Promotion Int. 30(1), 174-183 (2015).
6. Foucault M. Discipline and Punishment. Vintage Books, NY USA (1995).
7. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22(Suppl. 2), S133-S144 (1996).
8. Foss FM. Interleukin-2 fusion toxin: targeted therapy for cutaneous T cell lymphoma. Ann. NY Acad. Sci. 941 166-176 (2001).
9. Elinav E, Peer D. Harnessing nanomedicine for mucosal theranostics-a silver bullet at last ACS Nano 7, 2883-2890 (2013).
10. OHRP. www.hhs.gov/ohrp/sachrp/sachrpminrisk 20080131.html
11. Children and Young People's Health Outcomes Forum-Report of the Public Health and Prevention Sub-group. UK Department of Health (2013). www.gov.uk/government/uploads/system/uploads
12. Pierce R. "Complex calculations: ethical issues in involving at-risk healthy individuals in dementia research". J. Med. Ethics 36(9), 553-557 (2010).
13. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6(3),131-144 (2010).
14. Menéndez-González M. Routine lumbar puncture for the early diagnosis of Alzheimer's disease. Is it safe Front. Aging Neurosci. 6, 65 (2014).
15. Stolz M, Gottardi R, Raiteri R et al. Early detection of aging cartilage and osteoarthritis in mice and patient samples using atomic force microscopy. Nat. Nanotechnol. 4(3), 186-192 (2009).
16. Neely A, Perry C, Varisli B et al. Ultrasensitive and highly selective detection of Alzheimer's disease biomarker using two-photon Rayleigh scattering properties of gold nanoparticle. ACS Nano 3(9), 2834-2840 (2009).
17. Pan J, Liu Y, Feng SS. Multifunctional nanoparticles of biodegradable copolymer blend for cancer diagnosis and treatment. Nanomedicine (Lond.) 5(3), 347-360 (2010).
18. Chen WH, Xu XD, Jia HZ et al. Therapeutic nanomedicine based on dual-intelligent functionalized gold nanoparticles for cancer imaging and therapy in vivo. Biomaterials 34(34) 8798-8807 (2013).
19. Muthu MS, Leong DT, Mei L, Feng SS. Nanotheranostics-application and further development of nanomedicine strategies for advanced theranostics. Theranostics 4(6) 660-677 (2014).
20. Muthu MS, Singh S. Targeted nanomedicines: effective treatment modalities for cancer, AIDS and brain disorders. Nanomedicine (Lond.) 4(1), 105-118 (2009).
21. Kurado S, Yokoyama T, Tam JO et al. Multifunctional Tumor-Targeted Nanoparticles for Lung Cancer in Pulmonary Nanomedicine: Diagnostics, Imaging, and Therapeutics. Vij N (Ed.). Pan Stanford Publishing Pte Singapore (2012).
22. Wongrakpanich A, Geary SM, Joiner ML, Anderson ME Salem AK. Mitochondria-Targeting particles. Nanomedicine (Lond.) 9(16), 2531-2543 (2014).
23. Fang J, Tang L. The cell-Type specificity and endosomal escape of cell-penetrating peptides. Curr. Pharm. Des. 21(10),1351-1356 (2015).
24. Godard B, ten Kate L, Evers-Kiebooms G, Ayme S. Population genetic screening programmes: principles techniques, practices, and policies. Eur. J. Hum. Genet. 11(Suppl. 2), S49-S87 (2003).
25. Andorno R, Biller-Andorno N. The Risks of Nanomedicine and the Precautionary Principle in In Pursuit of Nanoethics. Gordijn B, Cutter AM (Eds). Springer, NY, USA (2014).
26. Lysaght T, Kerridge I. Rhetoric, power and legitimacy: a critical analysis of the public policy disputes surrounding stem cell research in Australia. Public Understanding Sci. 21(2) 195-210 (2012).
27. Weingart P, Salzmann C, Wormann S. The social embedding of biomedicine: an analysis of German media debates 1995-2004". Public Understanding Sci. 17(3) 381-396 (2008).
28. Nisbet M, Becker A. Public opinion about stem cell research 2002 to 2010. Public Opin. Quart. 78(4) 1003-1022 (2014).
29. Hett A. Nanotechnology-small matter, many unknowns (Report), Zurich, Swiss Reinsurance Company ("SwissRe"). www.denix.osd.mil/cmrmd/upload
30. Culver L, Egner H, Gallini S et al. Revisiting Risk Society: a conversation with Ulrich Beck. RCC Perspectives 6, 7-10 (2011).
31. Lautenschlager C, Schmidt C, Lehr CM, Fischer D Stallmach A. PEG-functionalized microparticles selectively target inflamed mucosa in inflammatory bowel disease. Eur. J. Pharm. Biopharm. 85(3 Pt A), 578-586 (2013).
32. Nielsen OH. New strategies for treatment of inflammatory bowel disease. Front. Med. (Lausanne) 1, 3 (2014).
33. Schmidt C, Lautenschlaeger C, Collnot EM et al. Nano-and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients. J. Control. Release 165(2), 139-145 (2013).
34. Duncan R, Richardson SC. Endocytosis and intracellular trafficking as gateways for nanomedicine delivery: opportunities and challenges. Mol. Pharm. 9(9), 2380-2402 (2012).
35. Stone J. The Routledge Dictionary of Latin Quotations. Routledge, London, UK, 140 (2004).
36. Farrell D, Ptak K, Panaro NJ, Grodzinski P. Nanotechnology-based cancer therapeutics-promise and challenge-lessons learned through the NCI Alliance for Nanotechnology in Cancer. Pharm. Res. 28(2), 273-278 (2011).
37. Theek B, Rizzo LY, Ehling J, Kiessling F, Lammers T. The theranostic path to personalized nanomedicine. Clin. Transl. Imaging 2(1), 66-76 (2014).
38. Lehr CM, Daum N, Schneider M, Schafer UF. Biological barriers-a need for novel tools in nanotoxicology and nanomedicine. Preface. Eur. J. Pharm. 77(3), 337 (2011).
39. Office of Human Research Protections. Institutional Review Board Guidebook. Chapter III. www.hhs.gov/ohrp/archive/irb/irb-chapter3.htm
40. Lammers T. Smart drug delivery systems: back to the future vs clinical reality. Int. J. Pharm. 454(1), 527-529 (2013).
41. Lupton D. Health promotion in the Digital Era: a critical commentary. Health Promotion Int. 30(1), 174-183 (2015).